Understanding Insulin Resistance in T1D
Insulin resistance isn’t just for type 2 diabetes. Many people with type 1 diabetes (T1D) develop features of insulin resistance as well. This hybrid form is often referred to as double diabetes. It’s more common than previously thought and can dramatically alter the course of care.
Studies suggest 25–40% of individuals with T1D eventually show signs of insulin resistance. Rates may be even higher in overweight adults or those diagnosed during adolescence.
Summary Table
| Topic | Key Points |
|---|---|
| Prevalence | Up to 40% of people with type 1 diabetes develop insulin resistance over time |
| Terminology | Double diabetes = T1D + insulin resistance features |
| Contributors | Obesity, sedentary lifestyle, genetics, puberty, chronic inflammation |
| Consequences | Higher insulin needs, weight gain, cardiovascular risk, kidney stress |
| Treatment Adjustments | Lifestyle support, GLP-1 receptor agonists, metformin, SGLT2 inhibitors, |
| Monitoring Shifts | Focus on waist size, lipids, blood pressure, and time in range (not just A1c) |
| Clinical Impact | Requires care from both a diabetes specialist and lipidologist or hypertension expert |
| Regional Relevance | Rising trend in Montgomery County, Maryland, especially in younger adults |
Why It Happens: Multiple Triggers at Play
Several factors increase the risk of insulin resistance in type 1 diabetes:
- Weight gain from excess insulin
- Sedentary lifestyle
- Visceral fat accumulation
- Genetic predisposition (especially family history of type 2 diabetes)
- Puberty and hormonal changes
- Low muscle mass and high carbohydrate intake
- Chronic stress and inflammation
As noted above, these influences can coexist and amplify each other. For instance, chronic hyperglycemia can promote inflammation, which further worsens insulin sensitivity.
What Changes Clinically
Insulin resistance raises the body’s need for insulin—even in T1D. That’s not just inconvenient. It’s risky.
Patients may experience:
- Rapid weight gain
- Higher risk of hypoglycemia due to erratic insulin needs
- Elevated triglycerides and blood pressure
- Faster onset of complications like kidney disease or cardiovascular disease
These patients are more prone to metabolic syndrome, despite having autoimmune diabetes. The overlap demands a broader and more tailored approach.
Holistic Monitoring Beyond A1c
A1c alone no longer tells the full story. With insulin resistance, other metrics gain importance:
- Waist circumference and BMI trends
- Lipid profile (especially triglycerides and non-HDL)
- Blood pressure (systolic and diastolic separately)
- Insulin dose per kilogram (insulin sensitivity estimate)
- ALT and liver fat (nonalcoholic fatty liver)
- Time-in-range on CGM (like FreeStyle Libre or Dexcom)
As a lipid specialist and clinical hypertension expert in Montgomery County, I frequently see T1D patients whose care shifts after recognizing insulin resistance. We often catch it early by looking at subtle changes in insulin dosing and metabolic markers.
Adjusting Treatment: Smarter Strategies
Managing double diabetes requires a multifaceted, common-sense approach. Insulin is still essential, but the overall plan expands:
Lifestyle & Nutrition
- Emphasize strength training and daily movement
- Limit processed carbs and reduce visceral fat
- Support gut health and circadian rhythm
Pharmacologic Tools
- GLP-1 receptor agonists for appetite and weight support
- Metformin to reduce hepatic glucose output and improve sensitivity
- SGLT2 inhibitors (cautiously in T1D; monitor for DKA)
- ACE inhibitors or statins when vascular risks are high
Personalized care, from multiple angles, makes the difference. This includes regular screening for lipid imbalances, kidney function, and even low testosterone in men.
Why Holistic, Individualized Care Matters
Each person with T1D and insulin resistance presents differently. Some develop abdominal obesity with high triglycerides. Others show early hypertension or signs of liver fat.
This is where thoughtful care matters most.
In our practice in Montgomery County, Maryland, we look at these patterns in the broader context. A patient with T1D and rising waist size may also have sleep apnea or low testosterone. Each detail matters—and must be integrated into a meaningful plan.
As a diabetes specialist and obesity specialist, I help patients view insulin resistance not as a failure, but as a turning point. It becomes a moment to pause, regroup, and shift the care strategy.
Final Thoughts
Insulin resistance in type 1 diabetes is common, subtle, and clinically significant. Left unrecognized, it increases the risk of complications. But with early detection and a comprehensive strategy, outcomes can dramatically improve.
- Insulin Resistance in Type 1 Diabetes: Pathophysiological, Clinical, and Therapeutic Relevance. Apostolopoulou M, Lambadiari V, Roden M, Dimitriadis GD. Endocrine Reviews. 2025;:bnae032. doi:10.1210/endrev/bnae032.
- Youth With Type 1 Diabetes Have Adipose, Hepatic, and Peripheral Insulin Resistance. Cree-Green M, Stuppy JJ, Thurston J, et al. The Journal of Clinical Endocrinology and Metabolism. 2018;103(10):3647-3657. doi:10.1210/jc.2018-00433.
- Cardiovascular Disease Risk Factors in Youth With Diabetes Mellitus: A Scientific Statement From the American Heart Association. Maahs DM, Daniels SR, de Ferranti SD, et al. Circulation. 2014;130(17):1532-58. doi:10.1161/CIR.0000000000000094.
- Insulin Resistance Is More Frequent in Type 1 Diabetes Patients With Long Disease Duration. Xie Y, Shi M, Ji X, et al. Diabetes/Metabolism Research and Reviews. 2023;39(6):e3640. doi:10.1002/dmrr.3640.
- Iatrogenic Hyperinsulinemia, Not Hyperglycemia, Drives Insulin Resistance in Type 1 Diabetes as Revealed by Comparison With GCK-MODY (MODY2). Gregory JM, Smith TJ, Slaughter JC, et al. Diabetes. 2019;68(8):1565-1576. doi:10.2337/db19-0324.
- Insulin Resistance in Patients With Type 1 Diabetes Assessed by Glucose Clamp Studies: Systematic Review and Meta-Analysis. Donga E, Dekkers OM, Corssmit EP, Romijn JA. European Journal of Endocrinology. 2015;173(1):101-9. doi:10.1530/EJE-14-0911.
About Dr. Gerti Tashko, MD
Dr. Gerti Tashko, MD, is a board-certified endocrinologist based in Montgomery County, Maryland. He is uniquely certified in endocrinology, lipidology, hypertension, and obesity medicine. His practice offers comprehensive, root-cause-focused metabolic and endocrine care, available both virtually and in person. He uses advanced diagnostics, personalized nutrition, and preventive medicine to optimize long-term health outcomes.



